We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App




New Blood Test Aims to Improve Management of Multiple Sclerosis

By LabMedica International staff writers
Posted on 12 Jul 2024

Multiple Sclerosis (MS) is an autoimmune, inflammatory, and neurodegenerative condition where axonal loss leads to irreversible neurological damage and disability. More...

Currently, approximately 2.8 million people globally are affected by MS, though this figure is likely underestimated due to underdiagnosis in underserved and remote areas lacking adequate neurological care and imaging facilities. While no cure exists for MS, available treatments aim to reduce the frequency of relapses, which are linked to nerve cell damage and the progression of the disease. There is a critical need for an accessible, affordable, and accurate blood test that can detect early signs of neuronal injury and disease activity. The neurofilament light chain (NfL) protein has been identified as a key biomarker for nerve cell damage. Now, a new blood test that measures levels of NfL could facilitate earlier detection of MS-related neuronal injury and improve disease management.

Siemens Healthineers (Forchheim, Germany), in collaboration with Novartis Pharma AG (Basel, Switzerland), will be soon making a blood test for MS disease management available. This test is designed to complement clinical assessments, imaging, and laboratory results to aid in predicting MS disease activity in patients with Relapsing Multiple Sclerosis (RMS). Early identification of the risk of MS-related neuronal injury in RMS patients would enable neurologists and other healthcare providers to manage the condition more effectively, potentially preventing relapses and disease progression.

Siemens’ NfL assay is intended for in vitro diagnostic use to quantitatively measure NfL in human serum and plasma. This blood test, when used in conjunction with clinical evaluations, imaging, and other laboratory data, aims to help identify RMS patients aged 18-55 who are at increased or decreased risk of MS disease activity. This activity is characterized by new or enlarging T2 magnetic resonance imaging lesions over two years. Blood-based biomarkers like NfL are enhancing the understanding of neurological diseases and are poised to significantly transform neurological practice. Siemens, with its Atellica Solution, is strategically positioned to support neurology with tests that can be administered on broadly accessible laboratory platforms, thus extending the availability of these tests to more healthcare practitioners and their patients.

"Neurofilament light chain, or NfL, has emerged as a leading biomarker of nerve cell damage,” said Dr. Dennis Gilbert, Head of Research, Development, and Innovation for Diagnostics at Siemens Healthineers. “Having access to a test that measures this protein capable of crossing the blood-brain barrier to support earlier prognostication of disease activity would be a critical scientific advancement for MS patients."


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: An innovative deep learning model can accurately predict MSI tumor and immune checkpoint inhibitor responsiveness (Photo courtesy of Jae-Ho Cheong/Yonsei University College of Medicine)

AI Model Accurately Predicts MSI Tumor and Immune Checkpoint Inhibitor Responsiveness

One in three people is expected to develop cancer in their lifetime, and a key factor in patient prognosis is the tumor’s microsatellite status—whether it is stable or shows microsatellite instability-high (MSI-H).... Read more

Pathology

view channel
Image: Virtual staining of label-free tissue in imaging mass spectrometry (Photo courtesy of Ozcan Lab/UCLA)

Deep Learning Advances Imaging Mass Spectrometry with Virtual Histological Detail

Imaging mass spectrometry (IMS) is a powerful technique that can map thousands of molecular species in biological tissues with exceptional chemical specificity. However, IMS is hindered by relatively low... Read more

Industry

view channel
Image: Alzheimer’s Association has released its first clinical practice guideline for blood-based biomarker tests (Photo courtesy of Alzheimer’s Association)

New Clinical Guidelines Recommend Use of Blood Tests Instead of Brain Scans for Alzheimer’s Diagnosis

Alzheimer’s disease is a progressive neurodegenerative condition that remains challenging to diagnose early and accurately, particularly in individuals with cognitive impairment. Despite the availability... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.